ArticlePloS one2025
Matching of XEN®45 and PRESERFLO™ MicroShunt cases: Outcomes of a 3-year follow-up.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients - a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Predicting bleb revision after XEN gel stent surgery in a real-world open-angle glaucoma cohort.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Referral for glaucoma surgery and types of surgery in different European regions in 2025, the EURACCUR study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare long-term outcomes of XEN®45 (XEN) and PRESERFLO™ MicroShunt (PRESERFLO) implants in the surgical management of glaucoma over a 3-year follow-up period, focusing on intraocular pressure (IOP) reduction, need of medication, surgical success, and postoperative complications.
methodsA retrospective, matched case control study was conducted, including 42 eyes with preceded implantation of a XEN or PRESERFLO. Patients were statistically matched using SPSS algorithms for glaucoma diagnosis, previous surgery, and demographics. Standardized success criteria defined surgical outcomes: complete success (IOP ≤ 15 mmHg or ≤ 18 mmHg without medications) and qualified success (IOP ≤ 15 mmHg with < 3 medications). Postoperative care and needling or revision interventions were recorded. Statistical analyzes included Wilcoxon, Mann-Whitney U, and t-tests.
resultsBoth devices significantly reduced IOP and glaucoma medication over 3 years. XEN reduced IOP from 22.1 ± 8.6 mmHg to 13.5 ± 3.8 mmHg, while PRESERFLO reduced IOP from 22.1 ± 6.6 mmHg to 12.6 ± 4.0 mmHg (p > 0.05 for between-groups, 3 years postoperative). Medication use decreased from 2.4 ± 1.0 to 0.9 ± 1.4 for XEN and 3.1 ± 1.1 to 1.1 ± 0.9 for PRESERFLO (p > 0.05 for between-groups). Surgical success rates were similar after 3 years. PRESERFLO showed fewer postoperative revisions (28.6% vs. 42.9% for XEN; p > 0.05). Early hypotony occurred more frequently with XEN (17 vs. 7 cases; p = 0.029).
conclusionBoth XEN and PRESERFLO effectively reduce IOP and the need for glaucoma medication, with comparable surgical success rates after 3 years. PRESERFLO demonstrated a lower revision rate and reduced frequency of early postoperative hypotony. These findings support both implants as viable options for minimally invasive glaucoma surgery, with low risk profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.